2025
Preliminary Evidence for Perturbation‐Based tACS‐EEG Biomarkers of Gamma Activity in Alzheimer's Disease
Palmisano A, Pezanko L, Cappon D, Tatti E, Macone J, Koch G, Smeralda C, Romanella S, Ruffini G, Rivolta D, Press D, Pascual‐Leone A, El‐Fakhri G, Santarnecchi E. Preliminary Evidence for Perturbation‐Based tACS‐EEG Biomarkers of Gamma Activity in Alzheimer's Disease. International Journal Of Geriatric Psychiatry 2025, 40: e70025. PMID: 39799469, DOI: 10.1002/gps.70025.Peer-Reviewed Original ResearchConceptsPeripheral neuroinflammationIdentification of novel biomarkersResponse to TACPatient's clinical phenotypeSpectral powerGABAergic dysfunctionNo significant correlationPrognostic valueInhibitory circuitryClinical severityClinical phenotypeAnimal modelsCognitive statusNeuroinflammatory markersAlzheimer's diseaseHuman patientsNeuroinflammatory biomarkersNovel biomarkersPatientsDisease severityTherapeutic targetGamma activityBiomarkersMild to moderate dementiaSignificant correlation
2024
The role of parvalbumin interneuron dysfunction across neurodegenerative dementias
Smeralda C, Pandit S, Turrini S, Reilly J, Palmisano A, Sprugnoli G, Hampel H, Benussi A, Borroni B, Press D, Rotenberg A, El Fakhri G, Koch G, Rossi S, Santarnecchi E. The role of parvalbumin interneuron dysfunction across neurodegenerative dementias. Ageing Research Reviews 2024, 101: 102509. PMID: 39306248, DOI: 10.1016/j.arr.2024.102509.Peer-Reviewed Original ResearchInterneuron dysfunctionCortical hyperexcitabilityTherapeutic targetCortical excitation/inhibition balanceRhythm disruptionFast-spikingPV+ cellsBasket neuronsPotential therapeutic targetInhibitory interneuronsExcitation/inhibition balanceOscillatory disruptionsSymptom onsetNovel biomarkersHyperexcitabilityDysfunctionNeuronal deathOscillatory activityDementia with Lewy bodiesPathophysiological frameworkClinical symptom onsetFrontotemporal dementia
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply